Serial gadolinium‐enhanced MRI in relapsing/remitting multiple sclerosis of varying disease duration
Abstract
In the planning of MRI protocols to monitor disease activity in multiple sclerosis (MS), the clinical subtype needs to be considered. In this serial gadolinium-enhanced MRI study, we demonstrated differences between patients with early relapsing/remitting MS and benign MS in both the production of new lesions and the occurrence of enhancement.
Get full access to this article
View all available purchase options and get full access to this article.
Information & Authors
Information
Published In
Copyright
© 1992 by Edgell Communications, Inc.
Publication History
Published online: January 1, 1992
Published in print: January 1992
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Perivascular tissue resident memory T cells as therapeutic target in multiple sclerosis, Expert Review of Neurotherapeutics, 20, 8, (835-848), (2020).https://doi.org/10.1080/14737175.2020.1776609
- Diagnosis of multiple sclerosis: revisions of the McDonald criteria 2017 – continuity and change, Current Opinion in Neurology, 32, 3, (327-337), (2019).https://doi.org/10.1097/WCO.0000000000000699
- Multiple sclerosis relapse: Qualitative findings from clinician and patient interviews, Multiple Sclerosis and Related Disorders, 27, (139-146), (2019).https://doi.org/10.1016/j.msard.2018.09.029
- Neuroimmunology, Atlas of Clinical Neurology, (669-697), (2019).https://doi.org/10.1007/978-3-030-03283-8_13
- Diagnose der Multiplen Sklerose: Revision der McDonald-Kriterien 2017Diagnosis of multiple sclerosis: revision of the McDonald criteria 2017, Der Nervenarzt, 89, 12, (1344-1354), (2018).https://doi.org/10.1007/s00115-018-0550-0
- Relationship of triple dose contrast enhanced lesions with clinical measures and brain atrophy in early relapsing-remitting multiple sclerosis: a two-year longitudinal study, Multiple Sclerosis Journal, 13, 2, (178-185), (2017).https://doi.org/10.1177/1352458506070758
- Ingested Type I Interferon: State of the Art as Treatment for Autoimmunity, Experimental Biology and Medicine, 227, 11, (981-988), (2016).https://doi.org/10.1177/153537020222701105
- Are there any body fluid markers of brain atrophy in multiple sclerosis?, Multiple Sclerosis Journal, 4, 3, (138-142), (2016).https://doi.org/10.1177/135245859800400310
- Strategies to identify sequences or antigens unique to multiple sclerosis, Multiple Sclerosis Journal, 2, 4, (184-194), (2016).https://doi.org/10.1177/135245859600200404
- Imaging in multiple sclerosis: A new spin on lesions, Journal of Medical Imaging and Radiation Oncology, 60, 5, (577-586), (2016).https://doi.org/10.1111/1754-9485.12498
- See more
Loading...
View Options
Get Access
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.